淋巴瘤合并COVID-19患者预后模型:多中心队列研究
该多中心队列纳入856例淋巴瘤合并COVID-19成人患者,前瞻性随访619例,中位随访66天。30天和100天死亡率分别为13%和23%,抗淋巴瘤治疗(含抗CD20方案)未影响生存。多因素分析识别年龄、性别、淋巴细胞和血小板计数4个易用因素与死亡风险相关,中危和高危组HR分别为3.79和8.85。
要点
- 淋巴瘤合并COVID-19患者30天死亡率为13%,100天为23%。
- 抗淋巴瘤治疗(包括含抗CD20方案)未影响患者生存。
- 年龄、性别、淋巴细胞和血小板计数构成简易预后模型,中危和高危组死亡风险显著升高。
核心结论
- 淋巴瘤患者不应被剥夺针对基础疾病的最佳可用治疗。
- 基于年龄、性别、淋巴细胞和血小板计数的模型可识别COVID-19死亡高风险患者。
研究设计与样本
- 多中心队列研究,纳入856例成人淋巴瘤合并COVID-19患者,其中619例为1年内前瞻性入组,中位随访66天(范围1-395)。
- 患者分为未住院队列(n=388)和住院队列(n=468),中位年龄63岁(范围19-94)。
- 研究注册于ClinicalTrials.gov,编号NCT04352556。
主要发现
- 30天死亡率为13%(95%CI 11%-15%),100天死亡率为23%(95%CI 20%-27%)。
- 抗淋巴瘤治疗(包括含抗CD20方案)未影响生存。
- 霍奇金淋巴瘤患者生存更优,部分与年龄显著更轻相关。
- 淋巴瘤诊断至COVID-19的时间间隔与死亡率呈负相关。
- 多因素分析识别年龄、性别、淋巴细胞和血小板计数4个因素与死亡风险相关,住院和未住院队列均适用;中危和高危组HR分别为3.79和8.85。
临床怎么用
- 对淋巴瘤合并COVID-19患者,应继续针对基础疾病给予最佳可用治疗。
- 可利用年龄、性别、淋巴细胞和血小板计数识别死亡高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin's lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
引用
- Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022. PMID: 34644385. doi:10.1182/bloodadvances.2021005691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。